Drug Profile
Glatiramer acetate - Lanco Biosciences
Alternative Names: copolymer-1 - Lanco Biosciences; LBS-102Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Lanco Biosciences
- Class Peptides; Polymers
- Mechanism of Action Immunomodulators; MHC class II gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Multiple sclerosis
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Multiple sclerosis in USA (Transdermal)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Multiple-sclerosis in USA (Transdermal, Needle-free injection)
- 12 Sep 2016 Chemical structure information added